U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H57N11O9.2C2H4O2
Molecular Weight 871.9779
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SELANK DIACETATE

SMILES

CC(O)=O.CC(O)=O.C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2CCC[C@H]2C(=O)NCC(=O)N3CCC[C@H]3C(O)=O

InChI

InChIKey=VHEHIIUPYDNNTE-UXAXJNOXSA-N
InChI=1S/C33H57N11O9.2C2H4O2/c1-19(45)26(35)29(49)41-20(8-2-3-13-34)30(50)44-17-6-11-23(44)28(48)40-21(9-4-14-38-33(36)37)31(51)43-16-5-10-22(43)27(47)39-18-25(46)42-15-7-12-24(42)32(52)53;2*1-2(3)4/h19-24,26,45H,2-18,34-35H2,1H3,(H,39,47)(H,40,48)(H,41,49)(H,52,53)(H4,36,37,38);2*1H3,(H,3,4)/t19-,20+,21+,22+,23+,24+,26+;;/m1../s1

HIDE SMILES / InChI

Molecular Formula C2H4O2
Molecular Weight 60.052
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C33H57N11O9
Molecular Weight 751.874
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

PubMed

PubMed

TitleDatePubMed
The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.
2001 Apr
Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress.
2003 Nov
A new property of the synthetic anxiolytic Selank and its derivatives.
2004 Jul-Aug
[Leu-enkephalin homogeneously labeled with tritium in studying the Selank inhibiting effect on the enkephalin-degrading enzymes of human plasma].
2004 May-Jun
[Effect of new synthetic anxiolytic selank on gastric wall blood flow and mesenteryc lymphatic vessels contractility in anesthetized rats].
2005 Feb
[Effects of the new peptide anxiolytic drug selank on the cardiovascular system functioning and respiration in cats].
2005 Jul-Aug
[Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation].
2006 Mar-Apr
[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders].
2008
[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].
2008
[Experimental hemorrhagic stroke: the study of neuropeptides (MIF, selank) in the intraperitoneal injection].
2009
[Experimental optimization of learning and memory processes by selank].
2010 Aug
Transcriptomic response of rat hippocampus and spleen cells to single and chronic administration of the peptide selank.
2010 Jan-Feb
Antiviral properties of structural fragments of the peptide Selank.
2010 Mar-Apr
Substance Class Chemical
Created
by admin
on Sat Dec 16 14:53:22 GMT 2023
Edited
by admin
on Sat Dec 16 14:53:22 GMT 2023
Record UNII
Q94Z9E92UU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SELANK DIACETATE
Common Name English
THR-LYS-PRO-ARG-PRO-GLY-PRO HOAC
Common Name English
TP-7 DIACETATE
Common Name English
SELANC DIACETATE
Common Name English
THR-LYS-PRO-ARG-PRO-GLY-PRO DIACETATE
Common Name English
Code System Code Type Description
PUBCHEM
155804769
Created by admin on Sat Dec 16 14:53:22 GMT 2023 , Edited by admin on Sat Dec 16 14:53:22 GMT 2023
PRIMARY PUBCHEM
FDA UNII
Q94Z9E92UU
Created by admin on Sat Dec 16 14:53:22 GMT 2023 , Edited by admin on Sat Dec 16 14:53:22 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY